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Summary.-Oestrogen (RE) and progesterone (RP) cytosolic receptors have been
studied in 59 clinically inflammatory tumours of the human breast. The results were
compared to those obtained in a series of 496 operable tumours. A single saturating
dose of oestradiol for RE and R5020 for RP was used and the cut-off between negative
and positive tumours was 100 fmol/g tissue. A significant difference was seen (P<0.02)
between the 2 classes of patients: (RE-, RP-) tumours were commoner among
clinically inflammatory tumours (48%) than among operable ones (28%), independ-
ently of menopause. Concerning the histological type (based on an assessment of
differentiation) and the histological grading (Scarff and Bloom) there was a signifi-
cant difference (P<0-001) between the 2 populations of tumours. No significant
difference was found in the distribution of RE and RP among the 3 histological types,
whereas a significant correlation existed between histological grading and RE
(P<0-02).
Finally, patients with RE+ clinically inflammatory tumours constitute a lower risk
group, especially when they are free of metastases at the time of diagnosis. The
presence of RE therefore seems to indicate, as in the operable tumour group, a
favourable prognosis.
THE clinically inflammatory tumours
are considered to be very severe carcin-
omas, reflecting serious imbalance in the
tumour-host relationship (Denoix, 1970).
They are of unfavourable prognosis and
are characterized by a particularly low
rate of survival at 5 years (- 150%)
(Fletcher & Montague, 1975; Lacour &
Hourtoule, 1967). These tumours very
seldom show any of the microscopic
features typical of clinically characterized
"inflammation" (Haagensen, 1971).
In the present study, we have simul-
taneously determined oestrogen receptors
(RE) and progesterone receptors (RP) in
inflammatory tumours of the human
breast, and have compared these results
with those obtained in primary operable
carcinomas. The prognostic value of RE
has been studied as well, since the presence
of RE should be a favourable prognostic
factor, independently of other known
factors in primary operable carcinomas
(Knight et al., 1977; Fletcher et al., 1978;
Cooke et al., 1979).
MATERIALS AND METHODS
Patients.-The present series includes 59
female patients with clinically inflammatory
tumours of the breast. Diagnosis and treat-
ment were performed at the Institut Gustave-
Roussy between March 1975 and December
1977. Metastatic work-up included chest
X-rays, mammograms, X-rays of the pelvis,
and bone orliverscans. Inflammatorytumours
are defined as tumours associated with local
inflammatory symptoms (cutaneous oedema,
skin redness and heat). These signs are either
localized in a part of or are in the whole
breast. The rapidly growing tumours (identi-J. C. DELARUE ET AL.
fied by careful history taking) were not
included in this study.
We have compared the 59 measurements
to those of 496 primary operable cases;
i.e. T1, T2 or T3<7 cm; No, N1; Mo according
to TNM classification.
Systemic treatment for patients with inflam-
matory tumours.-The gravity of this tumour
type is such that systemic treatment must be
given priority. This treatment combined
chemotherapy, radiotherapy and hormone
therapy:
Chemotherapy included several kinds of
drugs: either Adriamycin (40mg/M2 i.v.)+
Oncovin (1 mg i.v.)+Methotrexate (8 mg/
24 h s.c.) or Oncovin (1 mg i.v.)+5FU (300
mg/M2 i.v.)+Cyclophosphamide (250 mg/M2
i.v.) and was administered in 18-24 monthly
cycles.
Radiotherapy was given in two steps: a first
step between the 3rd and the 4th cycle
(45 Gy to the breast, chest wall and regional
lymph nodes over 41 weeks) and a second step
between the 4th and 5th cycle (20 Gy to the
breast over 2 weeks).
Hormone therapy was adapted to the
hormonal status of the patient: castration
by pelvic irradiation in the premenopausal
women with lymph-node involvement and
Tamoxifen in the others.
Receptor assay.-Immediately after large
biopsy under local anaesthesia, tumour
specimens (100-200 mg) were transported to
the laboratory on ice within a few minutes of
operation. Malignancy was verified by histo-
logical examination by the pathologist. The
samples were crushed at 00C in 3 volumes of
buffer (0O01M Tris-HCl, 0-012M dithiotreitol,
10% glycerol, pH 7.4) with an ultraturrax
(3-4 five-second bursts with 15-second cooling
intervals) and homogenized in a Teflon-glass
homogenizer.
The homogenate was centrifuged for 1 h at
105,000 g in the 50 Ti rotor ofa Beckman L2
centrifuge. The supernatant (=cytosol) was
used to determine RE and RP with a single-
saturating-dose method previously described
(May-Levin et al., 1977). Tumours with
levels of specific-binding sites greater than
100 fmol/g tissue were RE+, RP+. This
cut-off was arbitrarily chosen, and corre-
sponds to the limit of sensitivity of our
technique (Raynaud et al., 1977); it is com-
parable to those chosen by several authors
(Horwitz et al., 1975; Wittliff et al., 1976).
However, for positive results near the cut-off
point (3 results between 100 and 200 fmol/g
tissue) we considered the tumoral cell density
as determined by the pathologist; where cell
density was high, results were considered as
negative, where it was low, results were
positive.
Miscellaneous.-We have also determined:
(a) Histological types, which were divided
into 3 classes (Scarff & Torloni, 1968;
Contesso et al., 1977): "well-differentiated"
(tubular or papillary); "pleomorphic" (in-
filtrating ductal carcinoma with 2 components
mixed: tubular and trabecular); "atypical"
(infiltrating ductal carcinoma without tubular
or papillary components).
Our series had only one medullary adeno-
carcinoma with lymphoplasmocytic stroma.
(b) Histological grading according to WHO
and Scarff and Bloom (Bloom, 1950; Bloom
& Richardson, 1957) taking into considera-
tion: the degree of differentiation; nuclear
pleomorphism; mitotic activity.
(c) Tumour cell density (see above).
Labelled steroids (oestradiol for RE, R
5020 for RP) were purchased from New
England Nuclear Corp. (6072 Dreieich, W.
Germany).
Statistical significance between groups was
determined bythe x2 test and adjustment test
of Boyd & Doll (1954). Disease-free survival
rates were calculated by the Kaplan-Meier
method (1958) and curves compared by the
log-rank test (Peto et al., 1976, 1977).
RESULTS
Histological characteristics and hormone
receptors
Pre- and post-menopausal cases had the
same distribution ofallhistological charac-
teristics, allowing us to combine the 2
populations for our study.
There was a significant difference
(P < 0-001) between operable and inflam-
matory tumours in terms of histological
type (Table I). Operable tumours were
more often pleomorphic, inflammatory
tumours more often atypical. On the other
hand, no significant difference was found
in the distribution of RE among the 3
histological types, either for operable
tumours or for inflammatory ones (Table
II).
There was a significant difference
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TABLE I.-Histological comparison between operable and inflammatory tumours
Histological Well-
types differentiated
Operable 23 (5%)
Inflammatory 4 (7%)
Pleomorphic*
297 (61%)
17 (31%)
Atypical*
106 (22%)
34 (62%)
Other
forms
60 (12%)
0
P < 0-001.
Histological typing was not available in 10 operable tumours and 4 inflammatory tumours.
* See Material and Methods.
TABLE II.-Relationship between histological type and oestrogen receptors in operable and
inflammatory tumours (RE- < 100fmol/g tissue)
Histological types
Operable tumours RE-
RE+
Inflammatory tumours RE-
RE+
Well-
differentiated
8 (35%)
15 (65%)
1 (25%)
3 (75%)
Pleomorphic*
129 (43%)
168 (57%)
9 (53%)
8 (47%)
Atypical*
57 (54%)
49 (46%)
18 (53%)
16 (47%)f
NS
NS
RE+, RE- =tumours with and without oestrogen receptors.
RP+, RP-, tumours with and without progesterone receptors.
TABLE III.-Comparison between operable Types of tumours and hormone receptors
and inflammatory tumours according to There was a statistically significant
histological grade (Scarf-Bloom) difference (P< 0.02) in the distribution of
Histological RE and RP between operable and inflam-
grade I II III matory tumours (Table V). In the inflam-
Tumours matory tumours the proportion of (RE-,
Operable 85 (17%) 227 (47%) 175 (36%) RPj cases was higher (48%) than in the
Inflammatory 0 17 (30%) 40 (70%) operable group (28%).
P< 0001. This difference applied to both pre- and
Histological grading was not available in 7 oper- postmenopausal women, as shown i
able tumours and 2 inflammatory tumours. psmnpua oe,a hw
Table VI. Significance was obtained in an
(P< 0-001) between the 2 categories of adjustment test (Boyd & Doll, 1954).
tumours in terms of histological grading Prognostic value of hormone receptors (Table III).
A significant correlation was found We have tried to determine whether RE
(P< 0-02) between histological grading status influenced the evolution of the
and RE for inflammatory tumours only, disease. This has been done by studying
as shown in Table IV. Grade III are more the disease-free curves of RE+ and RE-
frequently RE- and Grade II more patients (Kaplan & Meier, 1958). For in-
frequently RE+; there was no tumour in flammatory tumours, Fig. 1 shows that
Grade I. the number of cases presenting with meta-
The results for RP paralleled those of stases at diagnosis is the same for RE+
RE, butthe difference was notstatistically tumours (11/28 patients) as for RE-
significant. tumours (10/30 patients). The slopes of
TABLE IV.-Relationship between histological grading and oestrogen receptors in operable
and inflammatory tumours
Histological grading
Operable tumours RE-
RE+
Inflammatory tumours RE-
RE+
I
35 (41%)
50 (59%)
0
0
II
107 (47%)
122 (53%)
5 (29%)
12 (71%)
III
87 (60%) NS
88 (50%)1
16 (38%)}
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TABLE V.-RE and RP in human mam-
mary carcinomas
Receptors
status
RE-, RP-
RE+, RP-
RE-, RP+
RE+ RP+
Tumours ~~~~A
Operable Inflammatory
28% (140) 48% (28)
18% (91) 19% (11)
15% (76) 5% (3)
38% (189) 28% (17)
P<0-02.
the curves, however, show more favour-
able evolution for patients with RE+
tumours (P < 0 01). If we exclude patients
with metastases at diagnosis, we obtain a
more significant difference (log-rank,
(P < 0 001) between the disease-free curves
of patients with RE+ and RE- tumours
(Fig. 2). Concerning the operable tumours,
the prognostic value ofRE is under study;
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FIG. 1.-RE and recurrence in all patients
with clinically inflammatory tumours.
RE ---- (n= 30) (1 patient lost to view).
RE+ (n = 28).
P < 0-01.
FiG. 2.-RE and recurrence in patients free
of metastasis at the time of diagnosis of
inflammatory tumours.
RE-- (n= 20).
RE+ (n= 17).
P < 0.001.
we operate very severe patient selection,
and we consider that a follow-up ofonly 36
months is insufficient for a population
with a good prognosis (80% at 5 years).
DISCUSSION
Until now, inflammatory tumours ofthe
breast have been categorized on the basis
of clinical criteria alone. The gravity of
this tumour type is such that systemic
treatment must be given priority (see
Materials and Methods). This study has
TABLE VI.-RE and RP in human mammary carcinomas according to hormonal status
Receptors
I A
Hormonal status
Premenopausal
Postmenopausal
Tumours
Operable
Inflammatory
Operable
Inflammatory
RE-, RP-
30% (66)
50% (15)
27% (74)
45% (13)
RE+, RP-
10% (23)
13% (4)
25% (68)
24% (7)
RE-, RP+
21% (48)
3% (1)
10% (28)
7% (2)
RE+, RP+
39% (87)
33% (10)
38% (102)
24% (7)
P < 0-02 with the adjustment test of Boyd & Doll (1954).
The number of patients is indicated in brackets.
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confirmed the high frequency of distant
metastases at diagnosis (21/59, or 36%),
but until now, it has not been possible
either to identify the mechanisms res-
ponsible for the clinical identity of these
tumours, or to determine the relevance of
certain aetiological factors (age, family
history, endocrine status, etc.).
Histological results confirmed that this
is a separate disease entity, 62% of the
tumours atypical, which agrees with other
authors (e.g. Haagensen, 1971) who found
that the atypical type accounted for 80%
of 59 cases. As opposed to our results,
Martin et al. (1978) found a relationship
between histological type andRE distribu-
tion, on the basis of classification into 2
categories: well-differentiated and pleo-
morphic with more than 50% differenti-
ation, and atypical and pleomorphic with
less than 50% differentiation.
As for the histological grading of Scarff
and Bloom, as has already been observed
(Sarrazin et al., 1978) we find these in-
flammatory tumours to be highly malig-
nant with 70% being classified as Grade
III, the most unfavourable group. While a
significant relationship between histo-
logical grading and RE distribution could
be shown only for the inflammatory
tumours, such a relationship (though not
statistically significant) was also seen for
the operable tumours. Our results are
identical to those reported by other
groups (Maynard etal., 1978; Furmanski et
al., 1980; King, 1980; McCarty et al.,
1980; Millis, 1980). Taken together, these
results confirm that RE and RP receptors
represent an aspect of cell differentiation
of tumours. Furthermore, other authors
(Meyer et al., 1977; Silvestrini et al., 1979)
have shown that tumours with a high
growth rate and labelling index are most
frequently without receptors.
The fact that inflammatory tumours
show a higher proportion of RE-, RP-
cases than the operable tumours is a
further argument for distinguishing be-
tween the 2 tumour types (McGuire et al.,
1975, 1977; May-Levin et al., 1977). Our
results thus indicate that, amidst this
population ofinflammatory tumours with
a generally poor prognosis, there is a
histo-biological subgroup with a still
worse prognosis.
The clinical progression seems to con-
firm these observations. The prognostic
value ofRE for the inflammatory tumours
is in keeping with results published for the
operable tumours (Knight et al., 1977;
Fletcher et al., 1978; Cooke et al., 1979;
Furmanski et al., 1980; Osborne et al.,
1980) even if sometimes (Blamey et al.,
1980) the prognostic value is limited to
the N+ tumours. Only Hilf et al. (1980a,b)
found no favourable prognostic index for
the operable RE+ tumours. Nevertheless,
we must point out that patients in our
study were all subjected to the same
systemic treatment; it is thuspossible that
the efficiency ofthe hormonal treatment is
at least partially responsible for the
favourable evolution of RE+ tumours,
which should be hormone sensitive.
Finally, we consider it interesting that
the frequency ofRE+ tumours is the same
in the pre-menopausal (46%) and the post-
menopausal (48%) groups. A study carried
out in parallel with ours at the Institute
Gustave-Roussy (Rouesse et al., 1979) for
comparison of current treatment modali-
ties (chemotherapy and hormone therapy)
for inflammatory tumours with the pre-
vious surgical approaches, has shown that
only pre-menopausal women benefit from
this approach (both in terms of survival
rate and duration of remission). However,
RE assay could not be carried out in all
patients, so that no correlation could here
be drawn.
The authors acknowledge the technical assistance
of Mireille Lemaout.
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